We are live on ! Find out more
LXRX icon

Lexicon Pharmaceuticals
LXRX

121 hedge funds and large institutions have $1.29B invested in Lexicon Pharmaceuticals in 2018 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 45 increasing their positions, 37 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

86% more call options, than puts

Call options by funds: $4.86M | Put options by funds: $2.62M

50% more funds holding in top 10

Funds holding in top 10: 2 → 3 (+1)

37% more capital invested

Capital invested by funds: $940M → $1.29B (+$351M)

22% more repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 37

1.11% less ownership

Funds ownership: 103.95% → 102.84% (-1.1%)

4% less funds holding

Funds holding: 126 → 121 (-5)

27% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 15

Holders
121
Holders Change
-5
Holders Change %
-3.97%
% of All Funds
2.77%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.07%
New
11
Increased
45
Reduced
37
Closed
15
Calls
$4.86M
Puts
$2.62M
Net Calls
+$2.25M
Net Calls Change
+$3.14M

Top Buyers

1
AG
Artal Group
Luxembourg
+$20.1M
2
Millennium Management
Millennium Management
New York
+$4.39M
3
BlackRock
BlackRock
New York
+$2M
4
PCM
Price Capital Management
Louisiana
+$1.38M
5
CLM
ClearBridge LLC (Maryland)
Maryland
+$1.31M

Top Sellers

1
UIM
USS Investment Management
United Kingdom
-$22.6M
2
State Street
State Street
Massachusetts
-$6.86M
3
TCM
Tekla Capital Management
Massachusetts
-$1.98M
4
PA
Pinnacle Associates
New York
-$1.19M
5
PAMU
Pictet Asset Management (UK)
United Kingdom
-$1.13M
Name Holding Trade Value Shares
Change 		Change in
Stake
Jacobs Levy Equity Management
26
Jacobs Levy Equity Management
New Jersey
$2.05M +$833K +81,463 +91%
Citigroup
27
Citigroup
New York
$2.02M +$1.11M +108,333 +181%
WS
28
Wedbush Securities
California
$1.82M -$41.4K -4,046 -3%
Morgan Stanley
29
Morgan Stanley
New York
$1.77M +$416K +40,700 +38%
TCIM
30
TIAA CREF Investment Management
New York
$1.62M +$354K +34,636 +35%
Stifel Financial
31
Stifel Financial
Missouri
$1.55M +$252K +24,608 +24%
CS
32
Credit Suisse
Switzerland
$1.51M +$781K +76,354 +155%
State of Wisconsin Investment Board
33
State of Wisconsin Investment Board
Wisconsin
$1.48M -$474K -46,300 -27%
UBS Group
34
UBS Group
Switzerland
$1.47M -$985K -96,264 -44%
Goldman Sachs
35
Goldman Sachs
New York
$1.39M +$490K +47,899 +71%
DekaBank Deutsche Girozentrale
36
DekaBank Deutsche Girozentrale
Germany
$1.36M +$20.5K +2,000 +2%
PCM
37
Price Capital Management
Louisiana
$1.35M +$1.38M +134,529 New
California Public Employees Retirement System
38
California Public Employees Retirement System
California
$1.3M -$90K -8,800 -8%
PPA
39
Parametric Portfolio Associates
Washington
$1.29M +$332K +32,475 +43%
Citadel Advisors
40
Citadel Advisors
Florida
$1.25M -$145K -14,202 -12%
Bank of America
41
Bank of America
North Carolina
$1.05M +$45.7K +4,471 +5%
TA
42
Teachers Advisors
New York
$1M +$66.3K +6,485 +8%
AllianceBernstein
43
AllianceBernstein
Tennessee
$1M +$91K +8,900 +12%
Victory Capital Management
44
Victory Capital Management
Texas
$982K -$46.2K -4,520 -5%
Swiss National Bank
45
Swiss National Bank
Switzerland
$960K – – –
D.E. Shaw & Co
46
D.E. Shaw & Co
New York
$932K +$325K +31,741 +69%
California State Teachers Retirement System (CalSTRS)
47
California State Teachers Retirement System (CalSTRS)
California
$794K +$5.17K +505 +0.8%
CM
48
Crestline Management
Texas
$758K +$646K +63,125 New
MCC
49
Malaga Cove Capital
California
$692K -$21K -2,054 -3%
JP Morgan Chase
50
JP Morgan Chase
New York
$684K -$443K -43,324 -43%
1
2
3 4 5

LXRX Hedge Fund Activity: Q2 2018 in Review

121 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Lexicon Pharmaceuticals (LXRX) for Q2 2018, worth a combined $1.29B — up 37% from $940M a quarter earlier.

Sellers outnumbered buyers: 15 funds closed out of LXRX and 11 opened new positions — a net loss of 4 holders — while 37 trimmed existing stakes and 45 added.

The largest buyer was Artal Group, adding an estimated $20.1M. The largest seller was USS Investment Management, exiting entirely with an estimated $22.6M sold.

  • 121 institutional investors held Lexicon Pharmaceuticals (LXRX) as of Q2 2018, down from 126 in Q1 2018.
  • Funds reported $1.29B of Lexicon Pharmaceuticals stock for Q2 2018, up 37% quarter-over-quarter.
  • 11 funds opened new Lexicon Pharmaceuticals positions in Q2 2018 and 15 closed out, a net change of -4 holders.
  • The largest Lexicon Pharmaceuticals buyer in Q2 2018 was Artal Group, an estimated $20.1M added.
  • The largest Lexicon Pharmaceuticals seller in Q2 2018 was USS Investment Management, an estimated $22.6M sold.

Based on aggregated 13F filings for Q2 2018.